Analysis of steroid hormone effects on xenografted human NF1 tumor Schwann cells

Cancer Biology and Therapy

Volumn 10, Issue 8, 2010, Pages 758-764

  Li, Hua ^a,b   Zhang, Xuelian ^a   Fishbein, Lauren ^a   Kweh, Frederick ^a   Thompson, Martha Campbell ^a,d   Perrin, George Q ^a   Muir, David ^a,d   Wallace, Margaret ^a,c,d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Estrogen; MPNST; Neurofibroma; NF1; Progesterone; Steroid hormones; Xenograft

Indexed keywords

ESTROGEN; KI 67 ANTIGEN; PLACEBO; PROGESTERONE;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEMALE; HORMONAL CARCINOGENESIS; HORMONE ACTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MOUSE; NERVE CELL CULTURE; NEUROFIBROMA; NEUROFIBROMATOSIS; NICK END LABELING; NONHUMAN; OVARIECTOMY; PRESCHOOL CHILD; SCHOOL CHILD; SCHWANN CELL; SCIATIC NERVE; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT;

ADOLESCENT; ADULT; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DRUG IMPLANTS; ESTROGENS; FEMALE; HUMANS; INFANT; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; NEUROFIBROMATOSIS 1; OVARIECTOMY; PROGESTERONE; SCHWANN CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 78049260041     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.8.12878     Document Type: Article

References (52)

1. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44:81-8.
2. Puls LE, Chandler PA. Malignant schwannoma in pregnancy. Acta Obstet Gynecol Scand 1991; 70:243-4.
3. Dugoff L, Sujansky E. Neurofibromatosis type 1 and pregnancy. Am J Med Genet 1996; 66:7-10.
4. Roth TM, Petty EM, Barald KF. The role of steroid hormones in the NF1 phenotype: focus on pregnancy. Am J Med Genet A 2008; 146:1624-33.
5. Roth TM, Ramamurthy P, Muir D, Wallace MR, Zhu Y, Chang L, et al. Influence of hormones and hormone metabolites on the growth of Schwann cells derived from embryonic stem cells and on tumor cell lines expressing variable levels of neurofibromin. Dev Dyn 2008; 237:513-24.
6. Roth TM, Ramamurthy P, Muir D, Wallace MR, Zhu Y, Roelen KF. Influence of hormones and hormone metabolites on the growth of schwann cells derived from embryonic stem cells and on tumor cell lines expressing variable levels of neurofibromin. Dev Dyn 2008; 237:1.
7. Lammert M, Mautner VF, Kluwe L. Do hormonal contraceptives stimulate growth of neurofibromas? A survey of 59 NF1 patients. BMC Cancer 2005; 5:16.
8. McLaughlin ME, Jacks T. Progesterone receptor expression in neurofibromas. Cancer Res 2003; 63:752-5.
9. Fishbein L, Zhang X, Fisher LB, Li H, Campbell-Thompson M, Yachnis A, et al. In vitro studies of steroid hormones in neurofibromatosis 1 tumors and Schwann cells. Mol Carcinogen 2007; 46:512-23.
10. Jung-Testas I, Schumacher M, Bugnard H, Baulieu EE. Stimulation of rat Schwann cell proliferation by estradiol: synergism between the estrogen and cAMP. Brain Res Devel Brain Res 1993; 72:282-90.
11. Jung-Testas I, Schumacher M, Robel P, Baulieu EE. Demonstration of progesterone receptors in rat Schwann cells. J Steroid Biochem Mol Biol 1996; 58:77-82.
12. Overdiek A, Winner U, Mayatepek E, Rosenbaum T. Schwann cells from human neurofibromas show increased proliferation rates under the influence of progesterone. Pediatr Res 2008; 64:40-3.
13. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51-7.
14. Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 2001; 158:501-13.
15. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994; 8:1019-29.
16. Perrin GQ, Fishbein L, Thomson SA, Thomas SL, Stephens K, Garbern JY, et al. Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line. J Neurosci Res 2007; 85:1347-57.
17. Perrin GQ, Li H, Fishbein L, Thomson SA, Hwang MS, Scarborough MT, et al. An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation. Lab Invest 2007; 87:1092-102.
18. Zhou JR, Yu L, Mai Z, Blackburn GL. Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice. Int J Cancer 2004; 108:8-14.
19. Tang AC, Nakazawa M, Romeo RD, Reeb BC, Sisti H, McEwen BS. Effects of long-term estrogen replacement on social investigation and social memory in ovariectomized C57BL/6 mice. Horm Behav 2005; 47:350-7.
20. McAsey ME, Cady C, Jackson LM, Li M, Randall S, Nathan BP, et al. Time course of response to estradiol replacement in ovariectomized mice: brain apolipoprotein E and synaptophysin transiently increase and glial fibrillary acidic protein is suppressed. Exp Neurol 2006; 197:197-205.
21. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 1995; 11:90-2.
22. Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 2000; 9:3055-64.
23. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002; 296:920-2.
24. Cabibi D, Zerilli M, Caradonna G, Schillaci L, Belmonte B, Rodolico V. Diagnostic and prognostic value of CD10 in periphernal nerve sheath tumors. Anticancer Res 2009; 29:3149-55.
25. Holtkamp N, Mautner VF, Friedrich RE, Harder A, Hartmann C, Theallier-Janko A, et al. Differentially-expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol 2004; 107:159-68.
26. Perry A, Kunz SN, Fuller CE, Banerjee R, Marley EF, Liapis H, et al. Differential NF1, p16 and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically-similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002; 61:702-9.
27. McCarron KF, Goldblum JR. Plexiform neurofibroma with and without associated malignant peripheral nerve sheath tumor: a clinicopathologic and immunohistochemical analysis of 54 cases. Mod Pathol 1998; 7:612-7.
28. Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol 2008; 35:1014-9.
29. Cunha KS, Barboza EP, Fonseca EC. Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics (Sao Paulo) 2008; 63:39-42.
30. Friedrich RE, Keiner D, Hagel C. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1. Anticancer Res 2007; 27:2085-90.
31. Kweh F, Zheng M, Kurenova E, Wallace M, Golubovskaya V, Cance WG. Neurofibromin interacts with the N-terminal domain of focal adhesion kinase. Molec Carcinogen 2009; 48:1005-17.
32. Li Y, Rao PK, Wen R, Song Y, Muir D, Wallace P, et al. Notch and Schwann cell transformation. Oncogene 2004; 23:1146-52.
33. Muir DF. Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression. Clin Exp Metastasis 1995; 13:303-14.
34. Mawrin C, Schulz S, Hellwig-Patyk A, Kirches E, Roessner A, Lendeckel U, et al. Expression and function of somatostatin receptors in peripheral nerve sheath tumors. J Neuropathol Exp Neurol 2005; 64:1080-8.
35. Cunha KS, Barboza EP, Da Fonseca EC. Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1. J Clin Pathol 2003; 56:758-63.
36. Hirose T, Tani T, Shimada T, Ishizawa K, Shimada S, Sano T. Immunohistochemical demonstration of EMA/Glut1-positive perineurial cells and CD34-positive fibroblastic cells in peripheral nerve sheath tumors. Mod Pathol 2003; 16:293-8.
37. Boyle JL, Haupt HM, Stern JB, Multhaupt HA. Tyrosinase expression in malignant melanoma, desmoplastic melanoma and peripheral nerve tumors. Arch Pathol Lab Med 2002; 126:816-22.
38. DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000; 105:1233-41.
39. Sherman LS, Atit R, Rosenbaum T, Cox AD, Ratner N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 2000; 275:30740-5.
40. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001; 20:97-105.
41. Upadhyaya M, Spurlock G, Kluwe L, Chuzhanova N, Bennett E, Thomas N, et al. The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas. Neurogenetics 2009; 10:251-63.
42. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009; 1:236-48.
43. Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res 2008; 14:1015-24.
44. Fishbein L, Eady B, Sanek N, Muir D, Wallace MR. Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. Cancer Genet Cytogenet 2005; 157:181-6.
45. Harder A, Rosche M, Reuss DE, Holtkamp N, Uhlmann K, Friedrich R, et al. Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. Eur J Cancer 2004; 40:2820-8.
46. Upadhyaya M, Spurlock G, Majounie E, Griffiths S, Forrester N, Baser M, et al. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Hum Mutat 2006; 27:716-20.
47. Zhang L, Li X, Zhao L, Zhang L, Zhang G, Wang J, Wei L. Nongenomic effect of estrogen on the MAPK signaling pathway and calcium influx in endometrial carcinoma cells. J Cell Biochem 2009; 106:553-62.
48. Colletta AA, Wakefield LM, Howell LM, van Roozendaal KE, Danielpour D, Ebbs SR, et al. Antioestrogens induce the secretion of active TGFβ from human fetal fibroblasts. Br J Cancer 1990; 62:405-9.
49. Butta A, MacLennan K, Flanders KC, Sacks NP, Smith I, McKinna A, et al. Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52:4261-4.
50. Todorova VK, Kaufmann Y, Luo S, Suzanne Klimberg V. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol 2010; [Epub ahead of print].
51. Bolanz KA, Kovacs GG, Landowski CP, Hediger MA. tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells. Mol Cancer Res 2009; 7:2000-10.
52. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, et al. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res 2009; 15:6327-40.